Squamous Cell Cancer of the Skin in a Patient on Maintenance Capecitabine for Metastatic Breast Cancer: A Case Report

Abstract Capecitabine is a widely used and effective oral chemotherapeutic agent for metastatic breast cancer and colorectal cancer; however, it is associated with several adverse effects. Of these effects, hand–foot syndrome (HFS) or palmar–plantar erythrodysesthesia, characterized by chronic infla...

Full description

Saved in:
Bibliographic Details
Published inJournal of cancer research and practice Vol. 11; no. 3; pp. 107 - 109
Main Authors Mahajan, Sidharth, Moore, Heather, Jolly, Puneet, Kimmick, Gretchen
Format Journal Article
LanguageEnglish
Published 01.07.2024
Online AccessGet full text

Cover

More Information
Summary:Abstract Capecitabine is a widely used and effective oral chemotherapeutic agent for metastatic breast cancer and colorectal cancer; however, it is associated with several adverse effects. Of these effects, hand–foot syndrome (HFS) or palmar–plantar erythrodysesthesia, characterized by chronic inflammation, particularly of the hands and feet, is most notable. Chronic inflammation increases the risk of squamous cell cancers. We present a unique case of a patient with metastatic breast cancer whose disease was controlled with capecitabine for over a decade. She experienced chronic grade 1–2 HFS and subsequently developed squamous cell skin cancer on the palms and soles. To the best of our knowledge, squamous cell cancer associated with capecitabine exposure has not been previously reported. This case report aims to shed light on this association, thereby expanding the existing literature on the topic.
ISSN:2311-3006
2311-3006
DOI:10.4103/ejcrp.eJCRP-D-24-00006